Article citationsMore>>

Albiges, L., Gurney, H., Atduev, V., Suarez, C., Climent, M.A., Pook, D., et al. (2023) Pembrolizumab Plus Lenvatinib as First-Line Therapy for Advanced Non-Clear-Cell Renal Cell Carcinoma (KEYNOTE-B61): A Single-Arm, Multicentre, Phase 2 Trial. The Lancet Oncology, 24, 881-891.
https://doi.org/10.1016/s1470-2045(23)00276-0

has been cited by the following article:

• TITLE: Getting to a Diagnosis: A Rare Case of TFE3 Translocation Renal Cell Carcinoma in a 22-Year-Old Male

  AUTHORS: Bayler Hinz, Jessup Kenyon

  KEYWORDS: Renal Cell Carcinoma, Metastatic, Retroperitoneal Mass, Tuberculosis, Primary Tumor

  JOURNAL NAME: Case Reports in Clinical Medicine, Vol.14 No.2, February 8, 2025

  ABSTRACT: Primary renal cell carcinoma (RCC) with metastasis is common with an estimated 30% of patients with RCC having metastases at the time of diagnosis. Evidence of metastatic RCC without a primary renal tumor is extremely rare with only a handful of cases citing this occurrence. Occasionally an unclear patient presentation requires thoughtful consideration of all the possibilities and results in a clinician reexamining the data to expand a differential, thus arriving at a diagnosis. This is the case of a 22-year-old who presented with diffuse lymphadenopathy, fever, cough, lower abdominal pain following a trip to India where the patient was hospitalized, initially believed to be tuberculosis. After multiple needle biopsies of lymph nodes and a retroperitoneal mass that were insufficient for a diagnosis, a wide excisional biopsy was performed that led to a diagnosis in our patient. The patient was diagnosed with metastatic TFE3-rearranged (MiT translocation) renal cell carcinoma and subsequently started on pembrolizumab and Lenvatinib followed by debulking surgery.